Drug Trial Radar · NCT00710788
Reduce Cardiovascular Calcifications to Reduce QT Interval in Dialysis
Last checked: Nov 20, 2026Latest source record: Feb 12, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
360
Actual
Start
Jan 2007
Primary completion
Sep 2010
Study completion Sep 2011
Sponsor
- Lead sponsor
- Azienda Sanitaria ASL Avellino 2Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 4, 2008
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Research proposal to evaluate the impact of different phosphate binders on the progression of cardiovascular calcification and QT dispersion in new haemodialysis patients.
Conditions
- Cardiovascular Mortality
Interventions
sevelamer phosphate-bindersDrug
1600 mg/day for 2 years
Calcium CarbonateDrug
Calcium carbonate 1 g/day for 2 years
Primary outcomes
What the sponsor says the trial is designed to measure.
- death due to cardiac arrhythmias or as sudden cardiac death defined as any deaths coded as "cardiac arrest, cause unknown" or "cardiac arrhythmia" without any exclusionsTime frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nephrology Division
Solofra, Avellino, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.